Pfizer underscores insatiable demand theory

20 Mar 2009

In what is becoming a familiar theme, US drug company Pfizer this week issued an acquisition related high grade bond that swiftly dropped to much lower yields after pricing.

It was priced only four weeks after Roche, another pharmaceutical, brought $16.5bn in the biggest US dollar bond offering yet.

This ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial